Literature DB >> 1138585

Effects of guanethidine and methyldopa on a standardized test for renin responsiveness.

S C Lowder, G W Liddle.   

Abstract

A standardized test for renin responsiveness, employing the dual stimulus of upright posture and the loop diuretic furosemide, was applied to 19 hypertensive patients in the untreated state and during therapy with the antihypertensive agents guanethidine and methyldopa. During therapy with guanethidine, 6 of 10 patients with "low-renin essential hypertension" experienced elevations of plasma renin activity to levles ordinarily diagnostic of "normal-renin" hypertension (P less than 0.05), whereas methyldopa had no significant effect on plasma renin activity in either "low-renin" or "normal-renin" patients. It is suggested that methyldopa has a negligible influence on renin responsiveness when stimulated under the above conditions and that it may be used during assessment of plasma renin activity in hypertensive patients whose blood pressure is too severely elevated for temporary withdrawal of therapy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138585     DOI: 10.7326/0003-4819-82-6-757

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  4 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

2.  The renin/angiotensin system.

Authors:  M R Lee
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

Review 3.  Effect of antihypertensive drugs on the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Peripheral plasma renin activity (PRA) in recipients with allograft artery stenosis; its diagnostic value in acute stage hypertension.

Authors:  J Zabka; J Stríbrná; V Kocandrle; Z Rotnáglová
Journal:  Int Urol Nephrol       Date:  1981       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.